Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management.
A wealth of data demonstrate that reduction of cholesterol levels is associated with benefit in reducing coronary artery disease risk. The magnitude of benefit observed with statin treatment, which acts primarily to reduce low-density lipoprotein cholesterol (LDL-C), is greater than that observed with any other lipid-modifying intervention, and data from large statin trials indicate that this benefit is caused by LDL-C reduction. Statin treatment is highly cost-effective compared with other accepted therapies, at least in the secondary prevention setting, and has a superior safety and tolerability profile. For the foreseeable future, LDL-C reduction will remain the goal of lipid-modifying therapy, and statins will remain the primary therapeutic modality for achieving that goal.
University of Oslo, Aker Hospital, Norway.
T R
TR
Pedersen
D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use*; D008078:Cholesterol, LDL / Q000097:blood*; D003327:Coronary Disease / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011379:Prognosis; D019821:Simvastatin / Q000191:economics / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D019821:Simvastatin